Cervical Cancer Clinical Trials

• Subject volunteered to participate in the study and signed an informed consent;

• Women aged ≥18 years and ≤75 years;

• Expected survival time ≥3 months;

• ECOG score 0-1;

• Gynecological malignancies such as recurrent or metastatic cervical cancer confirmed by histopathology and/or cytology after failure or intolerance to standard treatment or for which no standard treatment is available;

• Agree to provide 10 surgical specimens or fresh tissue samples of primary or metastatic tumors within 3 years;

• At least one measurable lesion meeting the RECIST v1.1 definition was required;

• No blood transfusion, colony-stimulating factor, any cell growth factor injection, or albumin injection were allowed within 14 days before the first use of the study drug, and the organ function level must meet the requirements;

• Urine protein ≤2+ or ≤1000g/24h;

⁃ No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;

⁃ The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;

⁃ For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, a serum or urine pregnancy test must be negative, and the patient must not be lactating; All enrolled patients should take adequate barrier contraception during the entire treatment cycle and for 6 months after the end of treatment.